XELOX for Metastatic Breast Cancer

University of Wisconsin (UW)

Status and phase: Completed; Phase 2

Conditions: Metastatic Breast Cancer

Treatments: Drug: Capecitabine and Oxaliplatin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00204776

2004-0340

CO04104

Details and patient eligibility

About

Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.

Enrollment: 37 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• preserved organ function
• good performance status
• no more than one prior therapy
• no active brain metastasis

Exclusion criteria

• No prior capecitabine or oxaliplatin
• no con-current therapy